This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Zacks.com featured highlights Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity
by Zacks Equity Research
Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity are part of the Zacks Screen of the Week article.
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 50% and 7.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains
by Vaishali Doshi
Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Puma Biotechnology (PBYI), Spotify (SPOT) and Oddity Tech (ODD), which investors can add to their portfolio to augment returns
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
by Zacks Equity Research
Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 68.75% and 5.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session.
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
by Zacks Equity Research
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
PBYI vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
by Zacks Equity Research
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.